
Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alopecia (Dermatology) pipeline landscape.
Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 15, 10, 1, 32, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alopecia (Dermatology) pipeline landscape.
Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 15, 10, 1, 32, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
3SBio Inc
Aclaris Therapeutics Inc
Addpharma Inc
Akaal Pharma Pty Ltd
Alexion Pharmaceuticals Inc
Almirall SA
AnaptysBio Inc
Aneira Pharma Inc
AnTolRx Inc
Applied Biology Inc
Berg LLC
Biolab Sanus Farmaceutica Ltda
BiologicsMD Inc
Bioquark Inc
BirchBioMed Inc
Caregen Co Ltd
Chong Kun Dang Pharmaceutical Corp
CK Regeon Inc
Concert Pharmaceuticals Inc
Cosmo Pharmaceuticals NV
Dermaliq Therapeutics Inc
dNovo Inc
Eli Lilly and Co
Energenesis Biomedical Co Ltd
Equillium Inc
Exicure Inc
Follica Inc
Haplnscience Inc
HCell Inc
HCW Biologics Inc
Hope Medicine Inc
Horizon Therapeutics Plc
Inventage Lab Inc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Johnson & Johnson
JW Pharmaceutical Corp
Kedi Biomedical Co Ltd
Kintor Pharmaceutical Ltd
Kuhnil Pharmaceutical Co Ltd
LG Chem Ltd
Maxinovel Pharmaceuticals
METiS Pharmaceuticals
Mirae Cell Bio Co Ltd
Nepsone ehf
OliX Pharmaceuticals Inc
Omega Therapeutics Inc
OnQuality Pharmaceuticals LLC
Pfizer Inc
Phio Pharmaceuticals Corp
Ponce Therapeutics Inc
ProTransit Nanotherapy LLC
RiverTown Therapeutics Inc
Samson Clinical Pty Ltd
Shenzhen Chipscreen Biosciences Co Ltd
siRNAgen Therapeutics Corp
Sisaf Ltd
Soterios Ltd
Stemson Therapeutics Corp
Suzhou Zelgen Biopharmaceutical Co Ltd
TagCyx Biotechnologies
Technoderma Medicines Inc
Throne Biotechnologies Inc
Tigo GmbH
Triple Hair Inc
Tritech Biopharmaceuticals Co Ltd
Turn Biotechnologies Inc
VasoDynamics Ltd
Companies Mentioned
3SBio Inc
Aclaris Therapeutics Inc
Addpharma Inc
Akaal Pharma Pty Ltd
Alexion Pharmaceuticals Inc
Almirall SA
AnaptysBio Inc
Aneira Pharma Inc
AnTolRx Inc
Applied Biology Inc
Berg LLC
Biolab Sanus Farmaceutica Ltda
BiologicsMD Inc
Bioquark Inc
BirchBioMed Inc
Caregen Co Ltd
Chong Kun Dang Pharmaceutical Corp
CK Regeon Inc
Concert Pharmaceuticals Inc
Cosmo Pharmaceuticals NV
Dermaliq Therapeutics Inc
dNovo Inc
Eli Lilly and Co
Energenesis Biomedical Co Ltd
Equillium Inc
Exicure Inc
Follica Inc
Haplnscience Inc
HCell Inc
HCW Biologics Inc
Hope Medicine Inc
Horizon Therapeutics Plc
Inventage Lab Inc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Johnson & Johnson
JW Pharmaceutical Corp
Kedi Biomedical Co Ltd
Kintor Pharmaceutical Ltd
Kuhnil Pharmaceutical Co Ltd
LG Chem Ltd
Maxinovel Pharmaceuticals
METiS Pharmaceuticals
Mirae Cell Bio Co Ltd
Nepsone ehf
OliX Pharmaceuticals Inc
Omega Therapeutics Inc
OnQuality Pharmaceuticals LLC
Pfizer Inc
Phio Pharmaceuticals Corp
Ponce Therapeutics Inc
ProTransit Nanotherapy LLC
RiverTown Therapeutics Inc
Samson Clinical Pty Ltd
Shenzhen Chipscreen Biosciences Co Ltd
siRNAgen Therapeutics Corp
Sisaf Ltd
Soterios Ltd
Stemson Therapeutics Corp
Suzhou Zelgen Biopharmaceutical Co Ltd
TagCyx Biotechnologies
Technoderma Medicines Inc
Throne Biotechnologies Inc
Tigo GmbH
Triple Hair Inc
Tritech Biopharmaceuticals Co Ltd
Turn Biotechnologies Inc
VasoDynamics Ltd
Table of Contents
184 Pages
- Introduction
- Global Markets Direct Report Coverage
- Alopecia - Overview
- Alopecia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Alopecia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Alopecia - Companies Involved in Therapeutics Development
- 3SBio Inc
- Aclaris Therapeutics Inc
- Addpharma Inc
- Akaal Pharma Pty Ltd
- Alexion Pharmaceuticals Inc
- Almirall SA
- AnaptysBio Inc
- Aneira Pharma Inc
- AnTolRx Inc
- Applied Biology Inc
- Berg LLC
- Biolab Sanus Farmaceutica Ltda
- BiologicsMD Inc
- Bioquark Inc
- BirchBioMed Inc
- Caregen Co Ltd
- Chong Kun Dang Pharmaceutical Corp
- CK Regeon Inc
- Concert Pharmaceuticals Inc
- Cosmo Pharmaceuticals NV
- Dermaliq Therapeutics Inc
- dNovo Inc
- Eli Lilly and Co
- Energenesis Biomedical Co Ltd
- Equillium Inc
- Exicure Inc
- Follica Inc
- Haplnscience Inc
- HCell Inc
- HCW Biologics Inc
- Hope Medicine Inc
- Horizon Therapeutics Plc
- Inventage Lab Inc
- Japan Tobacco Inc
- Jiangsu Hengrui Medicine Co Ltd
- JN Biosciences LLC
- Johnson & Johnson
- JW Pharmaceutical Corp
- Kedi Biomedical Co Ltd
- Kintor Pharmaceutical Ltd
- Kuhnil Pharmaceutical Co Ltd
- LG Chem Ltd
- Maxinovel Pharmaceuticals
- METiS Pharmaceuticals
- Mirae Cell Bio Co Ltd
- Nepsone ehf
- OliX Pharmaceuticals Inc
- Omega Therapeutics Inc
- OnQuality Pharmaceuticals LLC
- Pfizer Inc
- Phio Pharmaceuticals Corp
- Ponce Therapeutics Inc
- ProTransit Nanotherapy LLC
- RiverTown Therapeutics Inc
- Samson Clinical Pty Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- siRNAgen Therapeutics Corp
- Sisaf Ltd
- Soterios Ltd
- Stemson Therapeutics Corp
- Suzhou Zelgen Biopharmaceutical Co Ltd
- TagCyx Biotechnologies
- Technoderma Medicines Inc
- Throne Biotechnologies Inc
- Tigo GmbH
- Triple Hair Inc
- Tritech Biopharmaceuticals Co Ltd
- Turn Biotechnologies Inc
- VasoDynamics Ltd
- Alopecia - Drug Profiles
- (cyclosporine A + minoxidil + RT-175) - Drug Profile
- Product Description
- Mechanism Of Action
- AB-101 - Drug Profile
- Product Description
- Mechanism Of Action
- AB-102 - Drug Profile
- Product Description
- Mechanism Of Action
- AB-103 - Drug Profile
- Product Description
- Mechanism Of Action
- AB-105 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AD-106 - Drug Profile
- Product Description
- Mechanism Of Action
- AI-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AKP-11 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ANR-001 - Drug Profile
- Product Description
- Mechanism Of Action
- Antisense RNAi Oligonucleotides for Autoimmune Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- ARQ-255 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ATI-501 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- baricitinib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BL-3000 - Drug Profile
- Product Description
- Mechanism Of Action
- BMD-1141 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BQ-A - Drug Profile
- Product Description
- Mechanism Of Action
- calcitriol - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CB-0311 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cell Therapy for Alopecia - Drug Profile
- Product Description
- Mechanism Of Action
- Cell Therapy for Coronavirus Disease 2019 (COVID-19), Alopecia Areata and Type 1 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cerdulatinib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CKD-843 - Drug Profile
- Product Description
- Mechanism Of Action
- CKHT-5108 - Drug Profile
- Product Description
- Mechanism Of Action
- crisaborole - Drug Profile
- Product Description
- Mechanism Of Action
- CS-12192 - Drug Profile
- Product Description
- Mechanism Of Action
- CS-12328 - Drug Profile
- Product Description
- Mechanism Of Action
- CU-40101 - Drug Profile
- Product Description
- Mechanism Of Action
- CWL-080061 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- daxdilimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- delgocitinib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- deuruxolitinib phosphate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DLQ-01 - Drug Profile
- Product Description
- Mechanism Of Action
- Drug for Alopecia Areata - Drug Profile
- Product Description
- Mechanism Of Action
- Drugs to Agonize Aryl Hydrocarbon Receptor for Alopecia, Vitiligo and Pemphigus - Drug Profile
- Product Description
- Mechanism Of Action
- dutasteride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ENERGIF-701 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EQ-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- etrasimod - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- finasteride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- finasteride LA - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GT-20029 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Hair loss - Drug Profile
- Product Description
- Mechanism Of Action
- HC-0100 - Drug Profile
- Product Description
- Mechanism Of Action
- HC-017AA - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HCW-9302 - Drug Profile
- Product Description
- Mechanism Of Action
- HMI-115 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HS-301 - Drug Profile
- Product Description
- Mechanism Of Action
- HuABC-2 - Drug Profile
- Product Description
- Mechanism Of Action
- interferon beta-1b - Drug Profile
- Product Description
- Mechanism Of Action
- ivarmacitinib sulfate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- jaktinib hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KI-1104 - Drug Profile
- Product Description
- Mechanism Of Action
- KI-1105 - Drug Profile
- Product Description
- Mechanism Of Action
- lithium gluconate - Drug Profile
- Product Description
- Mechanism Of Action
- LR-19030 - Drug Profile
- Product Description
- Mechanism Of Action
- Max-3 - Drug Profile
- Product Description
- Mechanism Of Action
- minoxidil - Drug Profile
- Product Description
- Mechanism Of Action
- minoxidil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MN-709 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MTS-003 - Drug Profile
- Product Description
- Mechanism Of Action
- NG-13 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Oligonucleotide to Inhibit SFRP1 for Alopecia - Drug Profile
- Product Description
- Mechanism Of Action
- Oligonucleotides 1 for Androgenic Alopecia - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OLX-104C - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OQL-071 - Drug Profile
- Product Description
- Mechanism Of Action
- Peptide for Alopecia and Wounds - Drug Profile
- Product Description
- Mechanism Of Action
- Personalized Hair Stem Cells - Drug Profile
- Product Description
- Mechanism Of Action
- Protein to Antagonize PPAR Gamma-2 for Obesity, Alopecia, Osteoporosis and Rheumatoid Arthritis - Drug Profile
- Product Description
- Mechanism Of Action
- PT-002mn - Drug Profile
- Product Description
- Mechanism Of Action
- PTN-103A - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PTN-103C - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pyrilutamide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RCGD-423 - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and Graft Arteriosclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- ritlecitinib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rosnilimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Samcyprone - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SIS-023 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Cardiac Hypertrophy - Drug Profile
- Product Description
- Mechanism Of Action
- Stem Cell Therapy for Alopecia - Drug Profile
- Product Description
- Mechanism Of Action
- STS-01 - Drug Profile
- Product Description
- Mechanism Of Action
- TAGX-0003 - Drug Profile
- Product Description
- Mechanism Of Action
- TDM-105795 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tesnatilimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TH-07 - Drug Profile
- Product Description
- Mechanism Of Action
- TRN-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- UK-5099 - Drug Profile
- Product Description
- Mechanism Of Action
- Alopecia - Dormant Projects
- Alopecia - Discontinued Products
- Alopecia - Product Development Milestones
- Featured News & Press Releases
- Mar 26, 2022: Nearly 40% of adults with alopecia areata taking OLUMIANT 4-mg saw at least 80% scalp hair coverage at 52 weeks in Lilly's pivotal phase 3 studies
- Mar 07, 2022: Kintor concludes enrolment of Phase II alopecia trial in China
- Mar 06, 2022: Completion of patient enrollment in phase II clinical trial of KX-826 in China for the treatment of AGA in female patients
- Mar 02, 2022: Kintor begins dosing Phase II androgenic alopecia treatment trial in US
- Feb 04, 2022: Kintor doses first subject in US Phase I trial of dermatology asset
- Feb 03, 2022: Kintor Pharmaceutical: Voluntary announcement first subject dosing in phase I clinical trial of GT20029 (ar-protac) in the United States
- Jan 25, 2022: Hope Medicine announces US FDA clearance for phase II clinical trial of a first-in-class monoclonal antibody, HMI-115, in androgen alopecia
- Jan 11, 2022: 3SBio announces submission and acceptance of the application for the market launch of 5% Minoxidil foam
- Jan 04, 2022: Concert Pharmaceuticals completes enrollment in THRIVE-AA2 phase 3 clinical trial evaluating CTP-543 for Alopecia Areata
- Jan 03, 2022: Kintor begins dosing in androgenic alopecia treatment trial in China
- Nov 24, 2021: Kintor Pharma receives IND clearance by NMPA for KX-826's pivotal study to treat male alopecia patients
- Nov 15, 2021: AnaptysBio announces positive rosnilimab healthy volunteer phase 1 top-line data
- Nov 12, 2021: Kintor Pharma announces dosing of first patient in phase II clinical trial of KX-826 for the treatment of androgenic alopecia female patients in China
- Oct 25, 2021: Concert Pharmaceuticals completes enrollment in THRIVE-AA1 phase 3 clinical trial evaluating CTP-543 for alopecia areata
- Sep 30, 2021: OLUMIANT significantly improved hair regrowth to at least 80% scalp coverage as early as 24 weeks across first completed phase 3 studies for alopecia areata
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Alopecia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Companies, 2022 (Contd..2)
- Number of Products under Development by Companies, 2022 (Contd..3)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Companies, 2022 (Contd..3)
- Products under Development by Companies, 2022 (Contd..4)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Alopecia - Pipeline by 3SBio Inc, 2022
- Alopecia - Pipeline by Aclaris Therapeutics Inc, 2022
- Alopecia - Pipeline by Addpharma Inc, 2022
- Alopecia - Pipeline by Akaal Pharma Pty Ltd, 2022
- Alopecia - Pipeline by Alexion Pharmaceuticals Inc, 2022
- Alopecia - Pipeline by Almirall SA, 2022
- Alopecia - Pipeline by AnaptysBio Inc, 2022
- Alopecia - Pipeline by Aneira Pharma Inc, 2022
- Alopecia - Pipeline by AnTolRx Inc, 2022
- Alopecia - Pipeline by Applied Biology Inc, 2022
- Alopecia - Pipeline by Berg LLC, 2022
- Alopecia - Pipeline by Biolab Sanus Farmaceutica Ltda, 2022
- Alopecia - Pipeline by BiologicsMD Inc, 2022
- Alopecia - Pipeline by Bioquark Inc, 2022
- Alopecia - Pipeline by BirchBioMed Inc, 2022
- Alopecia - Pipeline by Caregen Co Ltd, 2022
- Alopecia - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
- Alopecia - Pipeline by CK Regeon Inc, 2022
- Alopecia - Pipeline by Concert Pharmaceuticals Inc, 2022
- Alopecia - Pipeline by Cosmo Pharmaceuticals NV, 2022
- Alopecia - Pipeline by Dermaliq Therapeutics Inc, 2022
- Alopecia - Pipeline by dNovo Inc, 2022
- Alopecia - Pipeline by Eli Lilly and Co, 2022
- Alopecia - Pipeline by Energenesis Biomedical Co Ltd, 2022
- Alopecia - Pipeline by Equillium Inc, 2022
- Alopecia - Pipeline by Exicure Inc, 2022
- Alopecia - Pipeline by Follica Inc, 2022
- Alopecia - Pipeline by Haplnscience Inc, 2022
- Alopecia - Pipeline by HCell Inc, 2022
- Alopecia - Pipeline by HCW Biologics Inc, 2022
- Alopecia - Pipeline by Hope Medicine Inc, 2022
- Alopecia - Pipeline by Horizon Therapeutics Plc, 2022
- Alopecia - Pipeline by Inventage Lab Inc, 2022
- Alopecia - Pipeline by Japan Tobacco Inc, 2022
- Alopecia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Alopecia - Pipeline by JN Biosciences LLC, 2022
- Alopecia - Pipeline by Johnson & Johnson, 2022
- Alopecia - Pipeline by JW Pharmaceutical Corp, 2022
- Alopecia - Pipeline by Kedi Biomedical Co Ltd, 2022
- Alopecia - Pipeline by Kintor Pharmaceutical Ltd, 2022
- Alopecia - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
- Alopecia - Pipeline by LG Chem Ltd, 2022
- Alopecia - Pipeline by Maxinovel Pharmaceuticals, 2022
- Alopecia - Pipeline by METiS Pharmaceuticals, 2022
- Alopecia - Pipeline by Mirae Cell Bio Co Ltd, 2022
- Alopecia - Pipeline by Nepsone ehf, 2022
- Alopecia - Pipeline by OliX Pharmaceuticals Inc, 2022
- Alopecia - Pipeline by Omega Therapeutics Inc, 2022
- Alopecia - Pipeline by OnQuality Pharmaceuticals LLC, 2022
- Alopecia - Pipeline by Pfizer Inc, 2022
- Alopecia - Pipeline by Phio Pharmaceuticals Corp, 2022
- Alopecia - Pipeline by Ponce Therapeutics Inc, 2022
- Alopecia - Pipeline by ProTransit Nanotherapy LLC, 2022
- Alopecia - Pipeline by RiverTown Therapeutics Inc, 2022
- Alopecia - Pipeline by Samson Clinical Pty Ltd, 2022
- Alopecia - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
- Alopecia - Pipeline by siRNAgen Therapeutics Corp, 2022
- Alopecia - Pipeline by Sisaf Ltd, 2022
- Alopecia - Pipeline by Soterios Ltd, 2022
- Alopecia - Pipeline by Stemson Therapeutics Corp, 2022
- Alopecia - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
- Alopecia - Pipeline by TagCyx Biotechnologies, 2022
- Alopecia - Pipeline by Technoderma Medicines Inc, 2022
- Alopecia - Pipeline by Throne Biotechnologies Inc, 2022
- Alopecia - Pipeline by Tigo GmbH, 2022
- Alopecia - Pipeline by Triple Hair Inc, 2022
- Alopecia - Pipeline by Tritech Biopharmaceuticals Co Ltd, 2022
- Alopecia - Pipeline by Turn Biotechnologies Inc, 2022
- Alopecia - Pipeline by VasoDynamics Ltd, 2022
- Alopecia - Dormant Projects, 2022
- Alopecia - Dormant Projects, 2022 (Contd..1)
- Alopecia - Dormant Projects, 2022 (Contd..2)
- Alopecia - Dormant Projects, 2022 (Contd..3)
- Alopecia - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Alopecia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.